ACA
DFTX

Avoro Capital Advisors’s Definium Therapeutics DFTX Stock Holding History

Avoro Capital Advisors’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$338M Buy
7,188,888
+2,188,888
+44% +$54.1M 3.04% 13
2026
Q1 		$94.5M Hold
5,000,000
– – 0.93% 21
2025
Q4 		$67M Buy
+5,000,000
New +$61.9M 0.66% 22

Other funds holding DFTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Avoro Capital Advisors's DFTX Position: Q2 2026 in Review

Avoro Capital Advisors increased its Definium Therapeutics (DFTX) stake by 44% in Q2 2026, buying an estimated $54.1M and bringing the position to 7,188,888 shares worth $338M. The position accounts for 3.04% of the portfolio, ranked #13.

Avoro Capital Advisors first reported a position in DFTX in Q4 2025 and has held it in 3 quarters since. 361 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

  • Avoro Capital Advisors held 7,188,888 shares of Definium Therapeutics worth $338M as of Q2 2026.
  • Avoro Capital Advisors bought 2,188,888 Definium Therapeutics shares in Q2 2026, an estimated $54.1M.
  • Definium Therapeutics made up 3.04% of Avoro Capital Advisors's portfolio in Q2 2026, its #13 holding.
  • Avoro Capital Advisors first reported a position in Definium Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 361 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Avoro Capital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.